These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23096369)

  • 1. [Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
    Durin O; Donato G; Nanetti M; Foffa A; Inama G
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):16S-20S. PubMed ID: 23096369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM
    Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschr Med; 2012 Jan; 154(1):20. PubMed ID: 22641998
    [No Abstract]   [Full Text] [Related]  

  • 6. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
    Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation in atrial fibrillation: a new era has begun].
    Moser M; Bode C
    Hamostaseologie; 2012; 32(1):37-9. PubMed ID: 22124808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in oral anticoagulation for atrial fibrillation.
    Singh M; Adigopula S; Patel P; Kiran K; Khosla S
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):395-407. PubMed ID: 20965952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation: epidemiology, prognosis and therapy.
    Rutzen-Lopez H; Khanna V; Reynolds MR
    Minerva Med; 2011 Jun; 102(3):187-207. PubMed ID: 21593721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Morales-Vidal S; Schneck MJ; Flaster M; Biller J
    Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
    Liem TK; Deloughery TG
    Semin Vasc Surg; 2011 Sep; 24(3):157-61. PubMed ID: 22153026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Khemasuwan D; Suramaethakul N
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.